Solid lipid nanoparticles (SLNs, sLNPs), or lipid nanoparticles (LNPs), are nanoparticles composed of lipids. They are a novel pharmaceutical drug delivery system (and part of nanoparticle drug delivery), and a novel pharmaceutical formulation.[1][2] LNPs as a drug delivery vehicle were first approved in 2018 for the siRNA drug, Onpattro.[3] LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).[4] .
True, the brain is the body's command center, but the immune system—unlike our organs—is not in one place. Immune cells rove freely through the blood and into most of our tissues and can respond relatively independently to local conditions.
Antibodies attacking brain tissue can trigger neuropsychiatric symptoms. Certain infections can trigger an abnormal immune response, whereby antibodies mistakenly attack healthy cells in the brain which can result in basal ganglia encephalitis.
Typically, cells of the immune system are not able to cross the BBB. This helps prevent brain inflammation. Unfortunately, sometimes, pathogens damage the BBB, enabling them to leave the blood and enter the brain. As a result of the damage, immune cells also enter the brain in an attempt to kill the invading organisms. When this happens, the person may experience:
Meningitis – Inflammation of the meninges, the outer membrane of the brain and spinal cord
Encephalitis - Inflammation of the brain
